{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039867","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.561424+00:00","generated_at":"2026-06-12T02:45:13.137924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Terns Pharma Q2 net loss $17.9M; positive Phase 2a NASH data for TERN-501","bullets":["Net loss of $17.9M ($0.25 per share) vs $13.9M a year ago; R&D spend $14.2M.","Cash $285.6M, expected to fund operations into 2026.","Positive Phase 2a DUET trial: TERN-501 met all endpoints in NASH; 45% mean liver fat reduction at 6mg.","TERN-701 Phase 1 for CML and TERN-601 Phase 1 for obesity both on track to start H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039867","json":"https://secwatch.observer/filing/0000950170-23-039867.json","markdown":"https://secwatch.observer/filing/0000950170-23-039867.md","text":"https://secwatch.observer/filing/0000950170-23-039867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023039867/0000950170-23-039867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023039867/tern-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:45:13.137924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041ffb0a191e7394de4ff1a74ff125f0ed21ce6e","claim":"Terns Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.9 million for the quarter ended June 30, 2023.","evidence_excerpt":"Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023039867/0000950170-23-039867-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Net income","value":"Net loss was $17.9 million for the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}